Dual Targeting of Extramedullary Myeloma Treatment
- A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death - in adults...
- The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group.
- This finding is notably relevant for individuals with pre-existing cardiovascular disease.
Ozempic and Cardiovascular Risk: New findings Demand Closer Scrutiny
What Happened? A Closer Look at teh SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events - including heart attack, stroke, and cardiovascular death – in adults with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated significant weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. This translates to a hazard ratio of 1.33, indicating a 33% increased risk. However, it’s crucial to note that the trial did *not* meet its primary endpoint of reducing MACE, despite the significant weight loss observed in the semaglutide group (an average of approximately 15% of body weight).
| Outcome | Semaglutide group (%) | Placebo group (%) | Hazard Ratio |
|---|---|---|---|
| Major Adverse Cardiovascular Event (MACE) | 6.5 | 4.9 | 1.33 |
| Cardiovascular Death | 3.7 | 2.9 | 1.29 |
| Non-Fatal Stroke | 2.6 | 1.7 | 1.55 |
| Non-Fatal Heart Attack | 1.9 | 1.3 | 1.47 |
Who is Affected? Understanding the Patient Population
This finding is notably relevant for individuals with pre-existing cardiovascular disease. The SELECT trial specifically enrolled participants with a history of established cardiovascular disease, including heart attack, stroke, or peripheral artery disease. it’s crucial to emphasize that the trial did *not* include patients with type 2 diabetes; all participants had obesity but not diabetes. This raises questions about the potential cardiovascular effects of semaglutide in different patient populations.
The average age of participants was 61 years, and approximately half were women. This demographic information is important for understanding the generalizability of the findings to broader populations.
Why Dose This Matter? implications for Clinical Practice
The SELECT trial challenges the widely held belief that semaglutide is a safe and effective weight loss medication for all. The increased risk of cardiovascular events, even in the context of significant weight loss, necessitates a more cautious approach to prescribing this drug. Clinicians should carefully assess the cardiovascular risk profile of each patient before initiating semaglutide therapy, particularly those with pre-existing heart conditions.